Timolol Gel for Epistaxis in Hereditary Hemorrhagic Telangiectasia

Phase 2 Completed 27 enrolled Washington University School of Medicine

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a double-blinded, randomized controlled trial to evaluate the efficacy of an intranasal topical timolol gel in the care for epistaxis in adults with hereditary hemorrhagic telangiectasia.

Timeline

Start: 2019-10-20
Primary completion: 2020-05-20
Completion: 2020-05-20

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper no definitive conclusions on the superiority of timolol can be drawn. PMID 32940653 ↗

Publications

Peterson AM, Lee JJ, Kallogjeri D, Schneider JS, Chakinala MM, Piccirillo JF. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2020 Nov 1;146(11):1006-1014. doi: 10.1001/jamaoto.2020.3025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Timolol	Other / unclassified	2 mg	Intranasal